Global HIV Drugs Market to Exceed $15.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on HIV Drugs market. The world market for HIV Drugs is projected to exceed $15.5 billion by the year 2015. Market growth is driven by rising prevalence of the condition worldwide, and increasing use of HAART therapy. The antiretroviral drugs used in the treatment of HIV/AIDS have transformed the life threatening condition with a short survival rate, into a manageable condition.

HIV Drugs: A Global Strategic Business Report

Globally, prevalence of HIV continues to rise. As of 2008, an estimated 33.9 million people were surviving with this life-threatening infection worldwide. The antiretroviral treatment aims at recovery from the damage caused by HIV. Anti-retroviral treatment, called as post-exposure prophylaxis, on early start after infection, can decrease the chances of infection. Globally, there is an increasing use of HAART or Highly Active Antiretroviral Therapy, which represent combinations involving minimum of 3 drugs related to 2 classes of antiretroviral agents.

The United States dominates the global HIV drugs market as stated by the new market research report on HIV drugs market. Segment-wise, Nucleoside Reverse Transcriptase Inhibitors represent the largest drug class in the global HIV drug market. Major drugs in this category include Ziagen, Retrovir, Hivid, Videx, Zerit, Epivir, Viread, and Combivir. NRTIs also represent the largest drug class in the US market. Other leading drugs in the market include Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors.

Key players profiled in the report include Abbott Laboratories, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Merck & Co. Inc., Tibotec BVBA, ViiV Healthcare, VIRxSYS Corporation and Pharmacia & Upjohn LLC.

The report titled "HIV Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of HIV disease, prevalence, incidence, drug categories, marketed drugs, pipeline drugs, growth drivers, drug approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including United States, Canada, Japan, Europe, and Rest of World. The study also provides analytics for the global and US markets by drug class - NRTIs, NNRTIs, PIs and Others.

For more details about this comprehensive market research report, please visit -
http://www.strategyr.com/HIV_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website